The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Inclusion criteria

• ✓. Fully understand the study and signed the Informed Consent Form (ICF) voluntarily;
• ✓. Subjects with histologically and/or cytologically confirmed advanced and/or metastatic gastric adenocarcinoma (including adenocarcinoma at esophageal-gastric conjunction), esophageal squamous cell carcinoma, nasopharyngeal carcinoma, or head and neck squamous cell carcinoma, who meet the following conditions (not applicable to cohort 5, 6, 7, and 8):
• ✓. At least one measurable lesion (according to RECIST 1.1); Note: Any lesion which received radiotherapy treatment previously cannot be regarded as a target lesion, unless that it has definitely progressed after radiotherapy.
• ✓. Agree to provide archived tumor tissue specimens or have biopsy to collect tumor tissues for PD-L1 IHC measurement in the central laboratory;
• ✓. Males or females aged between 18 and 75 years old;
• ✓. ECOG score of 0-1;
• ✓. Life expectancy ≥ 3 months;
• ✓. The results of laboratory tests performed within 7 days prior to enrollment must meet the following criteria: